Genmab - what happens next?

Genmab is trading 11% higher today on the approval of Daratumumab. The approval came very fast - underlining the fact that the FDA and medical community have been very eager to get this treatment to patients - fast. Several analysts have adjusted their 12-month target to the 949-1000 range, but this is merely to reflect that they still recommend investors to …

Read more.

---
Darzalex (Daratumumab approved)

Darzalex (Daratumumab approved)

Today it was announced that Danish biotech company Genmab has its 2nd cancer drug approved. The U.S. FDA has approved DARZALEX™ injection for intravenous infusion for the treatment of patients with multiple myeloma. Genmab almost doubled their estimate for 2015 with a milestones from Janssen of 45 USD Million. We are so happy on behalf of the company, their shareholders …

Read more.